Regarding infused CD34+ cell numbers, there was no statistical difference between ALL and AML patients (p=0.4). No statistical difference was found between AML and ALL patients regarding median NE duration (15 days, p=0.9). This evidence concerns the gene CD34 and acute lymphoblastic leukemia.